New biomarkers in non-Hodgkin lymphoma and acute leukemias

Benjamín Rubio-Jurado; Lluvia Sugey Sosa-Quintero; Ivette Lenina Carrasco-Martinez; Armando Norato-Delgado; Eduardo García Luna Martínez; Sandra Guzmán-Silahua; Carlos Riebeling-Navarro; Arnulfo Hernan Nava-Zavala

doi:10.1016/bs.acc.2019.11.002

New biomarkers in non-Hodgkin lymphoma and acute leukemias

Benjamín Rubio-Jurado, Lluvia Sugey Sosa-Quintero, Ivette Lenina Carrasco-Martinez, Armando Norato-Delgado, Eduardo García Luna Martínez, Sandra Guzmán-Silahua, Carlos Riebeling-Navarro, Arnulfo Hernan Nava-Zavala

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Biomarkers play a critical role in the medical care of patients with cancer, including in early detection of the disease, diagnostic accuracy, risk stratification, treatment, and follow-up. Biomarkers in hematological malignancies can support the redefinition of the diagnosis and adjustments in the treatment plan. Biomarkers can be classified into 4 categories: (1) protein antigens, (2) cytogenetic abnormalities, (3) genetic polymorphisms, and (4) gene expression. Efforts in genomics, proteomics, and metabolomics to observe new biomarkers that contribute to the development of clinical medicine with greater precision in the strategies that improve prevention, diagnosis, and treatment of patients with malignant hematological disease. New biomarkers should accomplish several issues such as the biological plausibility, methodology used, analytical validation, intellectual property registry, and legal framework of application. This knowledge should be transferred to health professionals who can carry out the process of its implementation in clinical practice.

Original language	English
Title of host publication	Advances in Clinical Chemistry
Editors	Gregory S. Makowski
Publisher	Academic Press Inc.
Pages	19-53
Number of pages	35
Volume	96
ISBN (Print)	9780128211663
DOIs	https://doi.org/10.1016/bs.acc.2019.11.002
Publication status	Published - 2020

Publication series

Name	Advances in Clinical Chemistry
Volume	96
ISSN (Print)	0065-2423
ISSN (Electronic)	2162-9471

Bibliographical note

Publisher Copyright:
© 2020 Elsevier Inc.

All Science Journal Classification (ASJC) codes

Chemistry(all)
Clinical Biochemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/bs.acc.2019.11.002

Cite this

Rubio-Jurado, B., Sosa-Quintero, L. S., Carrasco-Martinez, I. L., Norato-Delgado, A., García Luna Martínez, E., Guzmán-Silahua, S., Riebeling-Navarro, C., & Nava-Zavala, A. H. (2020). New biomarkers in non-Hodgkin lymphoma and acute leukemias. In G. S. Makowski (Ed.), Advances in Clinical Chemistry (Vol. 96, pp. 19-53). (Advances in Clinical Chemistry; Vol. 96). Academic Press Inc.. https://doi.org/10.1016/bs.acc.2019.11.002

Rubio-Jurado, Benjamín ; Sosa-Quintero, Lluvia Sugey ; Carrasco-Martinez, Ivette Lenina ; Norato-Delgado, Armando ; García Luna Martínez, Eduardo ; Guzmán-Silahua, Sandra ; Riebeling-Navarro, Carlos ; Nava-Zavala, Arnulfo Hernan. / New biomarkers in non-Hodgkin lymphoma and acute leukemias. Advances in Clinical Chemistry. editor / Gregory S. Makowski. Vol. 96 Academic Press Inc., 2020. pp. 19-53 (Advances in Clinical Chemistry).

@inbook{fa2f4a9f2ca94fb498bba9a2759b1eec,

title = "New biomarkers in non-Hodgkin lymphoma and acute leukemias",

abstract = "Biomarkers play a critical role in the medical care of patients with cancer, including in early detection of the disease, diagnostic accuracy, risk stratification, treatment, and follow-up. Biomarkers in hematological malignancies can support the redefinition of the diagnosis and adjustments in the treatment plan. Biomarkers can be classified into 4 categories: (1) protein antigens, (2) cytogenetic abnormalities, (3) genetic polymorphisms, and (4) gene expression. Efforts in genomics, proteomics, and metabolomics to observe new biomarkers that contribute to the development of clinical medicine with greater precision in the strategies that improve prevention, diagnosis, and treatment of patients with malignant hematological disease. New biomarkers should accomplish several issues such as the biological plausibility, methodology used, analytical validation, intellectual property registry, and legal framework of application. This knowledge should be transferred to health professionals who can carry out the process of its implementation in clinical practice.",

author = "Benjam{\'i}n Rubio-Jurado and Sosa-Quintero, {Lluvia Sugey} and Carrasco-Martinez, {Ivette Lenina} and Armando Norato-Delgado and {Garc{\'i}a Luna Mart{\'i}nez}, Eduardo and Sandra Guzm{\'a}n-Silahua and Carlos Riebeling-Navarro and Nava-Zavala, {Arnulfo Hernan}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

doi = "10.1016/bs.acc.2019.11.002",

language = "English",

isbn = "9780128211663",

volume = "96",

series = "Advances in Clinical Chemistry",

publisher = "Academic Press Inc.",

pages = "19--53",

editor = "Makowski, {Gregory S.}",

booktitle = "Advances in Clinical Chemistry",

address = "United States",

}

Rubio-Jurado, B, Sosa-Quintero, LS, Carrasco-Martinez, IL, Norato-Delgado, A, García Luna Martínez, E, Guzmán-Silahua, S, Riebeling-Navarro, C & Nava-Zavala, AH 2020, New biomarkers in non-Hodgkin lymphoma and acute leukemias. in GS Makowski (ed.), Advances in Clinical Chemistry. vol. 96, Advances in Clinical Chemistry, vol. 96, Academic Press Inc., pp. 19-53. https://doi.org/10.1016/bs.acc.2019.11.002

New biomarkers in non-Hodgkin lymphoma and acute leukemias. / Rubio-Jurado, Benjamín; Sosa-Quintero, Lluvia Sugey; Carrasco-Martinez, Ivette Lenina; Norato-Delgado, Armando; García Luna Martínez, Eduardo; Guzmán-Silahua, Sandra; Riebeling-Navarro, Carlos; Nava-Zavala, Arnulfo Hernan.

Advances in Clinical Chemistry. ed. / Gregory S. Makowski. Vol. 96 Academic Press Inc., 2020. p. 19-53 (Advances in Clinical Chemistry; Vol. 96).

Research output: Chapter in Book/Report/Conference proceeding › Chapter

TY - CHAP

T1 - New biomarkers in non-Hodgkin lymphoma and acute leukemias

AU - Rubio-Jurado, Benjamín

AU - Sosa-Quintero, Lluvia Sugey

AU - Carrasco-Martinez, Ivette Lenina

AU - Norato-Delgado, Armando

AU - García Luna Martínez, Eduardo

AU - Guzmán-Silahua, Sandra

AU - Riebeling-Navarro, Carlos

AU - Nava-Zavala, Arnulfo Hernan

PY - 2020

Y1 - 2020

N2 - Biomarkers play a critical role in the medical care of patients with cancer, including in early detection of the disease, diagnostic accuracy, risk stratification, treatment, and follow-up. Biomarkers in hematological malignancies can support the redefinition of the diagnosis and adjustments in the treatment plan. Biomarkers can be classified into 4 categories: (1) protein antigens, (2) cytogenetic abnormalities, (3) genetic polymorphisms, and (4) gene expression. Efforts in genomics, proteomics, and metabolomics to observe new biomarkers that contribute to the development of clinical medicine with greater precision in the strategies that improve prevention, diagnosis, and treatment of patients with malignant hematological disease. New biomarkers should accomplish several issues such as the biological plausibility, methodology used, analytical validation, intellectual property registry, and legal framework of application. This knowledge should be transferred to health professionals who can carry out the process of its implementation in clinical practice.

AB - Biomarkers play a critical role in the medical care of patients with cancer, including in early detection of the disease, diagnostic accuracy, risk stratification, treatment, and follow-up. Biomarkers in hematological malignancies can support the redefinition of the diagnosis and adjustments in the treatment plan. Biomarkers can be classified into 4 categories: (1) protein antigens, (2) cytogenetic abnormalities, (3) genetic polymorphisms, and (4) gene expression. Efforts in genomics, proteomics, and metabolomics to observe new biomarkers that contribute to the development of clinical medicine with greater precision in the strategies that improve prevention, diagnosis, and treatment of patients with malignant hematological disease. New biomarkers should accomplish several issues such as the biological plausibility, methodology used, analytical validation, intellectual property registry, and legal framework of application. This knowledge should be transferred to health professionals who can carry out the process of its implementation in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85081289652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081289652&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/92d7a1b9-be9a-3ca8-a7b3-e337abe61cce/

U2 - 10.1016/bs.acc.2019.11.002

DO - 10.1016/bs.acc.2019.11.002

M3 - Chapter

AN - SCOPUS:85081289652

SN - 9780128211663

VL - 96

T3 - Advances in Clinical Chemistry

SP - 19

EP - 53

BT - Advances in Clinical Chemistry

A2 - Makowski, Gregory S.

PB - Academic Press Inc.

ER -

New biomarkers in non-Hodgkin lymphoma and acute leukemias

Abstract

Publication series

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this